1887
Euroroundup Open Access
Like 0

Abstract

In 2007, a European survey identified variation in country policies on public health management of invasive meningococcal disease (IMD). In 2009–10, the European Centre for Disease Prevention and Control (ECDC) published evidence-based guidance on IMD. We therefore surveyed again European countries to describe policies for managing IMD cases and contacts in 2013. We asked national IMD public health experts from 32 European countries to complete a questionnaire focusing on post-exposure prophylaxis (PEP) for IMD contacts and meningococcal vaccination. Proportions in 2007 and 2013 were compared using the chi-squared test. All 32 countries responded, with responses from two regions for Belgium and Italy; half stated having used ECDC guidance to update national recommendations. PEP was recommended to close contacts in 33 of 34 countries/regions, mainly ciprofloxacin for adults (29/32 countries) and rifampicin for children (29/32 countries). ECDC guidance for managing IMD contacts in airplanes was strictly followed by five countries/regions. Twenty-three countries/regions participated in both surveys. Compared with 2007, in 2013, more countries/regions recommended i) ceftriaxone for children (15/23 vs 6/20; p = 0.03), ii) PEP for all children in the same preschool group (8/23 vs 17/23; p = 0.02). More countries/regions recommended evidence-based measures for IMD public health management in 2013 than 2007. However, some discrepancies remain and they call for further harmonisation.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2016.21.5.30125
2016-02-04
2017-11-18
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2016.21.5.30125
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/21/5/eurosurv-21-30125-4.html?itemId=/content/10.2807/1560-7917.ES.2016.21.5.30125&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Surveillance of invasive bacterial diseases in Europe, 2011. Stockholm: ECDC; 2013. Available from: http://www.ecdc.europa. eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=994.
  2. Heymann DL. Control of communicable disease manual, nineteenth edition. American Public Health Association, 2008.
  3. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20-5. Available from:  https://doi.org/10.1097/INF.0b013e3182706b89  PMID: 22926207 
  4. Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774-83.  https://doi.org/10.1016/S1474-4422(12)70180-1  PMID: 22863608 
  5. European Centre for Disease Prevention and Control (ECDC). Surveillance of invasive bacterial diseases in Europe 2008/2009. Stockholm: ECDC; 2011. Available from: http://ecdc.europa.eu/en/publications/Publications/1107_SUR_IBD_2008-09.pdf
  6. Hastings L, Stuart J, Andrews N, Begg N. A retrospective survey of clusters of meningococcal disease in England and Wales, 1993 to 1995: estimated risks of further cases in household and educational settings. Commun Dis Rep CDR Rev. 1997;7(13):R195-200.
  7. Hoek MR, Christensen H, Hellenbrand W, Stefanoff P, Howitz M, Stuart JM. Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: a systematic review. Epidemiol Infect. 2008;136(11):1441-7.
  8. De Wals P, Hertoghe L, Borlée-Grimée I, De Maeyer-Cleempoel S, Reginster-Haneuse G, Dachy A, et al. Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts. J Infect. 1981;3(1) Suppl;53-61. Available from:  https://doi.org/10.1016/S0163-4453(81)80009-6  PMID: 7185953 
  9. Munford RS, Souza De Morais J, De EA, Taunay AE, Fraser DW, Feldman RA. Spread of meningococcal infection within households. Lancet. 1974;303(7869):1275-8. Available from:  https://doi.org/10.1016/S0140-6736(74)90022-1  PMID: 4134961 
  10. European Centre for Disease Prevention and Control (ECDC). Public health management of sporadic cases of invasive meningococcal disease and their contacts. Stockholm: ECDC; 2010. Available from: http://ecdc.europa.eu/en/publications/Publications/1010_GUI_Meningococcal_guidance.pdf
  11. Zalmanovici Trestioreanu A, Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev. 2011; (8):CD004785.  https://doi.org/10.1002/14651858.CD004785.pub4  PMID: 21833949 
  12. Hoek M, Hanquet G, Heuberger S, Stefanoff P, Zucs P, Ramsay M, et al. A European survey on public health policies for managing cases of meningococcal disease and their contacts. Euro Surveill. 2008;13(10):8060. PMID: 18445439 
  13. European Centre for Disease Prevention and Control (ECDC). ECDC technical report. Risk assessment guidelines for infectious diseases transmitted on aircraft. Stockholm: ECDC; 2009. Available from: http://www.ecdc.europa.eu/en/publications/publications/0906_ter_risk_assess ment_guidelines_for_infectious_diseases_transmitted_on_aircraft.pdf
  14. European Centre for Disease Prevention and Control (ECDC). Risk assessment guidelines for diseases transmitted on aircraft. PART 2: Operational guidelines for assisting in the evaluation of risk for transmission by disease. Stockholm: ECDC; 2010. Available from: http://ecdc.europa.eu/ en/publications/publications/1012_gui_ragida_2.pdf
  15. Stanwell-Smith RE, Stuart JM, Hughes AO, Robinson P, Griffin MB, Cartwright K. Smoking, the environment and meningococcal disease: a case control study. Epidemiol Infect. 1994;112(02):315-28. Available from:  https://doi.org/10.1017/S0950268800057733  PMID: 8150006 
  16. MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC, Roberts R, et al. United Kingdom Meningococcal Carriage Group. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12(6):950-7. Available from:  https://doi.org/10.3201/eid1206.051297  PMID: 16707051 
  17. Tully J, Viner RM, Coen PG, Stuart JM, Zambon M, Peckham C, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-50. Available from:  https://doi.org/10.1136/bmj.38725.728472.BE  PMID: 16473859 
  18. European Medicines Agency (EMA). 2008. Summary of product characteristics for Ciprofloxacin Bayer and associated names. London: EMA. [Accessed 30 Mar 2015]. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/Referrals_document/Ciprofloxacin_Bayer_30/WC500008075.pdf
  19. Girgis N, Sultan Y, Frenck RW Jr, El-Gendy A, Farid Z, Mateczun A. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr Infect Dis J. 1998;17(9):816-9.  https://doi.org/10.1097/00006454-199809000-00013  PMID: 9779768 
  20. Podgore JK, Girgis N, El-Refai M, Abdel-Monheim A. A double-blind randomized trial of cefixime compared to rifampin in the eradication of meningococcal pharyngeal carriage in a closed population. J Trop Med (Cairo). 1993;2(5):41-5.
  21. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2014. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf
  22. Hellenbrand W, Hanquet G, Heuberger S, Nielsen S, Stefanoff P, Stuart JM. What is the evidence for giving chemoprophylaxis to children or students attending the same preschool, school or college as a case of meningococcal disease? Epidemiol Infect. 2011;139(11):1645-55. Available from:  https://doi.org/10.1017/S0950268811001439  PMID: 21835067 
  23. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25.
/content/10.2807/1560-7917.ES.2016.21.5.30125
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error